iBio (IBIO) Asset Writedowns and Impairment (2018 - 2026)

iBio (IBIO) has 6 years of Asset Writedowns and Impairment data on file, last reported at $4.9 million in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 136.41% increase from a year earlier, with the FY2024 full-year figure at $3.1 million, down 36.93% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $4.9 million, up from $3.1 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for IBIO reached as high as $4.9 million in Q1 2026 and fell as low as -$17.1 million in Q1 2023.
• Historically, Asset Writedowns and Impairment has averaged -$1.1 million across 3 years, with a median of $1.2 million in 2022.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 448.67% in 2023 and fell as far as 82.95% in 2023.
• Year by year, Asset Writedowns and Impairment stood at $565000.0 in 2022, then jumped by 448.67% to $3.1 million in 2023, then surged by 59.29% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $4.9 million in Q1 2026, $3.1 million in Q4 2023, and $300000.0 in Q2 2023.